Rat B7-2/CD86 Antibody

Catalog #: MAB13401 Datasheet / COA / SDS

Catalog #	Availability	Size / Price	Qty
MAB13401
MAB13401-SP

IL‑2 Secretion Induced by B7‑2/CD86 and Neutralization by Rat B7‑2/CD86 Antibody.

1 Image

All B7-2/CD86 Antibodies

Product Details

Supplemental Products

Reviews

Summary Data Examples Preparation and Storage Reconstitution Calculator Background Product Datasheets Related Research Areas

Rat B7-2/CD86 Antibody Summary

Species Reactivity

Rat

Specificity

Detects rat B7‑2/CD86 in direct ELISAs and Western blots. In direct ELISAs, no cross-reactivity with recombinant rat B7-1, recombinant human B7-2, recombinant mouse (rm) B7-2, rmB7-H1, rmB7-H2, rmB7-H3, or rmPD‑L is observed.

Source

Monoclonal Mouse IgG₁ Clone # 199622

Purification

Protein A or G purified from hybridoma culture supernatant

Immunogen

Mouse myeloma cell line NS0-derived recombinant rat B7‑2/CD86
Met1-Ile250
Accession # NP_064466

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Endotoxin Level

<0.10 EU per 1 μg of the antibody by the LAL method.

Label

Unconjugated

Applications

Recommended Concentration

Sample

Neutralization

Measured by its ability to neutralize B7‑2/CD86 and PHA-induced IL‑2 secretion in the Jurkat human acute T cell leukemia cell line. Linsley, P. et al. (1990) Proc. Natl. Acad. Sci. 87:5031. The Neutralization Dose (ND₅₀) is typically 0.3-1.0 µg/mL in the presence of 1 µg/mL Recombinant Rat B7‑2/CD86 Fc Chimera and 10 µg/mL PHA.

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Scientific Data

Neutralization

View Larger

IL‑2 Secretion Induced by B7‑2/CD86 and Neutralization by Rat B7‑2/CD86 Antibody. Recombinant Rat B7-2/CD86 Fc Chimera (Catalog # 1340-B2) co-stimulates IL-2 secretion in the Jurkat human acute T cell leukemia cell line in the presence of PHA in a dose-dependent manner (orange line), as measured by the Human IL-2 Quantikine ELISA Kit (Catalog # D2050). IL-2 secretion elicited by Recombinant Rat B7-2/CD86 Fc Chimera (1 µg/mL) and PHA (10 µg/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Rat B7-2/CD86 Monoclonal Antibody (Catalog # MAB13401). The ND₅₀ is typically 0.3-1.0 µg/mL.

Reconstitution Calculator

Preparation and Storage

Reconstitution

Reconstitute at 0.5 mg/mL in sterile PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: B7-2/CD86

For optimal T cell expansion and activation, a signal induced by the engagement of the T cell receptor and a “co-stimulatory” signal(s) through distinct T cell surface molecules are required. Members of the B7 superfamily of counter-receptors were identified by their ability to interact with co-stimulatory molecules found on the surface of T cells. Members of the B7 superfamily are type I membrane proteins and include B7-1 (CD80), B7-2 (CD86), B7-H1 (PD-L1), B7-H2 (B7RP-1), B7-H3, and PD-L2 (1). B7-2 is expressed constitutively at low levels on most Antigen Presenting Cells (APC) and is rapidly upregulated upon cell activation (2). T cells express two different receptors (CD28 and CTLA-4) capable of binding both B7-1 and B7-2 (2). B7-2 binds to CD28 with the low affinity but binds to CTLA-4 with intermediate affinity. In contrast, B7-1 binds CD28 with intermediate affinity and CTLA-4 with high affinity. Additionally, these molecules have different kinetics for binding CD28 and CTLA-4 with B7-2 having a higher-binding dissociation kinetics (1). Engagement of CD28 by B7-2 increases T cell proliferation and IL-2, IL-4, and IFN-gamma production, thereby enhancing the immune response (3). In contrast, engagement of CTLA-4 is involved in the down-regulation of the immune response (4). Rat B7-2 cDNA encodes a 313 amino acid (aa) precursor protein containing a an extracellular domain, a transmembrane domain, and a cytoplasmic domain. Rat and human B7-1 share 54% aa identity.

References

Coyle, A.J. and J-C. Gutierrez-Ramos (2001) Nature Immunol. 2:203.
Sharpe, A.H. and G.J. Freeman (2002) Nature Reviews 2:116.
Freeman, G.J. et al. (1995) Immunity 5:523.
Walunas, T.L. et al. (1994) Immunity 1:405.

Entrez Gene IDs

942 (Human); 12524 (Mouse); 56822 (Rat); 102147235 (Cynomolgus Monkey)

Alternate Names

Activation B7-2 antigen; B70; B7-2 antigen; B72; B7-2; B-lymphocyte activation antigen B7-2; BU63; CD28 antigen ligand 2; CD28LG2B7-2 antigen); CD86 antigen; CD86 molecule; CD86; CTLA-4 counter-receptor B7.2; FUN-1; LAB72; MGC34413; T-lymphocyte activation antigen CD86